Description
Kanglaite Injection (KLT) is a botanical anticancer drug prepared as a micro-emulsion for intravenous use. It is produced by the state of art technology with active substance extracted from a natural herbal plant "semen coicis".
As a novel antineoplastic agent KLT has the following features.
- Killing cancer cells effectively while remarkably improving patient immune capacity;
- Synergistic function when combined with chemotherapy or radiation therapy;
- Providing high energy nutrition to treat cachexia;
- Relieving cancerous pain markedly to replace morphine;
- Improving patient quality of life and notably prolonging survival;
- Very slight adverse reaction
KLT has brought great benefits to over 550,000 cancer patients in more than 2,200 hospitals in China and become the market leader among all anticancer drugs in China in recent 4 years.
FDA approved KLT clinical study in USA in March 2001 and the phase I at Huntsman Cancer Institute, Salt Lake City, Utah was satisfactorily completed the year later.
Russian Federation approved KLT clinical study in January 2002 and the studies were smoothly ended in April 2003 with inspiring outcomes. In December 2003 the registration certificate was issued from Russian Ministry of Health and KLT was launched in Russia in July 2005.
Unique anticancer mechanisms of KLT have been verified by researchers at Johns Hopkins University, USA.
We are seeking agent to distribute KLT in other countries with satisfactory policy.
or
